Raloxifene as a treatment for cognition in women with schizophrenia: the influence of menopause status

Osteoporosis is a common bone disease that gradually reduces bone density and increases the risk of fractures. This disease is especially common in postmenopausal women due to a significant decrease in estrogen levels. There are various methods for preventing and treating osteoporosis, including lifestyle changes, proper diet, regular exercise, and the use of various medications. One of the effective drugs in this field is raloxifene tablets. Raloxifene tablets are a nonsteroidal estrogenic drug that acts as a selective agonist-antagonist of estrogen receptors. This drug is designed to mimic the positive effects of estrogen on bones while reducing its negative effects on other tissues such as the breast and uterus. Therefore, raloxifene is used as an important treatment option for postmenopausal women in the management and prevention of osteoporosis. Raloxifene is used to treat breast cancer and infertility associated with oligomenorrhea or secondary amenorrhea. Raloxifene is a new treatment that has recently become available for the prevention of osteoporosis of the spine. It is taken as a single pill daily. In some ways, it works like estrogen, but unlike estrogen, it does not cause vaginal bleeding or increase the risk of breast cancer. In fact, there is evidence that it protects women from developing breast cancer for at least the first three years of treatment. Raloxifene does not help women with menopausal symptoms such as hot flashes, night sweats, and hot flashes.

کلیدواژه ها:

Raloxifene ، breast cancer ، Bone ، Side Effects ، estrogen hormone